Moxifloxacin is a recently approved fluoroquinolone antibiotic with indications consistent with outpatient therapy.1 During clinical trials, moxifloxacin was found to prolong the QT interval. The clinical risk for resulting arrhythmias is unknown, but the approved labeling includes warnings against concurrent therapy with amiodarone, sotalol hydrochloride, quinidine, or procainamide hydrochloride. Recent articles2-4 highlight interest in QT prolongation in association with moxifloxacin and other fluoroquinolones. To proactively study compliance with approved labeling, we used a large, longitudinal pharmacy claims database to assess concomitant (overlapping) use of moxifloxacin and levofloxacin (as control) with amiodarone, sotalol, quinidine, or procainamide. Levofloxacin, initially marketed in January 1997, shares many properties with moxifloxacin but carries no labeled warning against concurrent therapy with amiodarone, sotalol, quinidine, or procainamide.5
Brinker A, Staffa J. Concurrent Use of Selected Agents With Moxifloxacin: An Examination of Labeling Compliance Within 1 Year of Marketing. Arch Intern Med. 2002;162(17):2011–2012. doi:10.1001/archinte.162.17.2011
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.